Merrimack Pharmaceuticals News

Merrimack Pharma Plans to Delist, Pending Holder Approval of Liquidation Plan

By Stephen Nakrosis Merrimack Pharmaceuticals on Tuesday said it filed with the Nasdaq regarding the company's plan to delist its securities from the exchange, subject to shareholder approval of the

WSJMay 1 06:00

Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution

Company Updates Potential Range of Initial Liquidating Distribution and Additional Dividend Information Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced that it has filed

BusinesswireMay 1 05:15

Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan

Merrimack Pharmaceuticals (MACK) said late Wednesday it has received a $225 million milestone payment from Ipsen and called for a special stockholder meeting on May 10 to approve a plan of dissolution

MT NewswiresMar 28 05:30

Merrimack Receives $225M Milestone Payment From Ipsen

Seeking AlphaMar 28 04:36

Merrimack Secures $225M Milestone Payment From Ipsen; Says It Is Unlikely That Any Additional Milestone Payments Will Become Payable

The company has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-l

BenzingaMar 28 04:34

Merrimack Receives $225 Million Milestone Payment From Ipsen

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.

BusinesswireMar 28 04:30

Merrimack Pharmaceuticals Proposes Liquidation Plan

TipRanksMar 8 05:52

Merrimack FY23 EPS $(0.08) Per Basic Share

Merrimack FY23 EPS $(0.08) Per Basic Share

BenzingaMar 8 05:34

Merrimack Pharmaceuticals 2023 Loss $1.2M >MACK

Merrimack Pharmaceuticals 2023 Loss $1.2M >MACK

Dow JonesMar 8 05:32

Merrimack Pharmaceuticals 2023 Loss/Shr 8c >MACK

Merrimack Pharmaceuticals 2023 Loss/Shr 8c >MACK

Dow JonesMar 8 05:32

Merrimack Reports Full Year 2023 Financial Results

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December 31, 2023.

Business WireMar 8 05:30

Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen

Merrimack Pharmaceuticals (MACK) said Tuesday it is entitled to receive a $225 million milestone payment from Ipsen after the US Food and Drug Administration approved the supplemental new drug applica

MT NewswiresFeb 14 18:15

Merrimack to Dissolve After FDA Nod Prompts $225 Million Payment

InvestingFeb 14 05:56

Merrimack Pharmaceuticals to Get $225M Milestone Payment After FDA's Supplemental NDA Approval

By Sabela Ojea Merrimack Pharmaceuticals said it will receive a $225 million milestone payment from Ipsen after the U.S. Food and Drug Administration approved the supplemental new drug application fo

WSJFeb 14 05:49

Merrimack Pharmaceuticals Weighs Dissolution Post FDA Approval

TipRanksFeb 14 05:34

Merrimack Management Estimates That The Aggregate Amount Of The Liquidating Dividend Payable To Stockholders Will Be In The Range Of Between Approximately $14.65 And $15.35 Per Share

Merrimack Management Estimates That The Aggregate Amount Of The Liquidating Dividend Payable To Stockholders Will Be In The Range Of Between Approximately $14.65 And $15.35 Per Share

BenzingaFeb 14 05:25

Merrimack Says Ipsen's FDA Approval Of Onivyde SNDA Triggers $225M Payment From Ipsen to Merrimack

Merrimack Says Ipsen's FDA Approval Of Onivyde SNDA Triggers $225M Payment From Ipsen to Merrimack

BenzingaFeb 14 05:24

Merrimack Spikes as Ipsen Wins FDA Label Expansion for Cancer Therapy

Seeking AlphaFeb 14 02:35

FDA Approves Irinotecan Liposome For First-line Treatment Of Metastatic Pancreatic Adenocarcinoma

On February 13, 2024, the Food and Drug Administration approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin, for the first-line treatme

BenzingaFeb 14 02:19

Merrimack Pharmaceuticals(MACK.US) Director Buys US$651.75K in Common Stocks

$Merrimack Pharmaceuticals(MACK.US)$ Director Andersen Eric purchased 49,550 shares of Common Stocks on Dec 26, 28, 2023 at an average price of $13.1535 for a total value of $651.75K. This transaction

Futu NewsDec 29, 2023 05:18